FR2321275B1 - - Google Patents

Info

Publication number
FR2321275B1
FR2321275B1 FR7614707A FR7614707A FR2321275B1 FR 2321275 B1 FR2321275 B1 FR 2321275B1 FR 7614707 A FR7614707 A FR 7614707A FR 7614707 A FR7614707 A FR 7614707A FR 2321275 B1 FR2321275 B1 FR 2321275B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR7614707A
Other languages
French (fr)
Other versions
FR2321275A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of FR2321275A1 publication Critical patent/FR2321275A1/fr
Application granted granted Critical
Publication of FR2321275B1 publication Critical patent/FR2321275B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR7614707A 1975-08-20 1976-05-14 Preparation d'insuline pour administration nasale Granted FR2321275A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB34576/75A GB1527605A (en) 1975-08-20 1975-08-20 Insulin preparation for intranasal administration

Publications (2)

Publication Number Publication Date
FR2321275A1 FR2321275A1 (fr) 1977-03-18
FR2321275B1 true FR2321275B1 (OSRAM) 1979-04-13

Family

ID=10367351

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7614707A Granted FR2321275A1 (fr) 1975-08-20 1976-05-14 Preparation d'insuline pour administration nasale

Country Status (5)

Country Link
JP (1) JPS6030651B2 (OSRAM)
BE (1) BE841871A (OSRAM)
DE (1) DE2620446A1 (OSRAM)
FR (1) FR2321275A1 (OSRAM)
GB (1) GB1527605A (OSRAM)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5145405A (ja) * 1974-10-16 1976-04-17 Unyusho Kowan Gijutsu Kenkyush Jibankairyokoho
JPS53115510A (en) * 1977-12-19 1978-10-09 Kitagawa Iron Works Co Support structure made by hardening weak soil
JPS53115509A (en) * 1977-12-19 1978-10-09 Kitagawa Iron Works Co Method of changing weak ground into stable ground
DE2917535C2 (de) * 1979-04-30 1986-10-30 Hoechst Ag, 6230 Frankfurt Gegen Denaturierung beständige Insulinlösungen
JPS58501125A (ja) * 1981-07-17 1983-07-14 ノルデイスク・インスリンラボラトリウム 安定な水性治療性インシユリン製剤及びその製造方法
CH657779A5 (de) * 1982-10-05 1986-09-30 Sandoz Ag Galenische zusammensetzungen enthaltend calcitonin.
IE56483B1 (en) * 1982-12-10 1991-08-14 Syntex Inc Lhrh preparations for intranasal administration
IL70489A0 (en) * 1982-12-29 1984-03-30 Armour Pharma Pharmaceutical compositions containing calcitonin
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
US4746508A (en) * 1983-06-06 1988-05-24 Beth Israel Hospital Assn. Drug administration
US4548922A (en) * 1983-06-06 1985-10-22 Beth Israel Hospital Drug administration
DE3443877A1 (de) * 1984-06-09 1985-12-12 Hoechst Ag Insulinzubereitungen, verfahren zu deren herstellung und deren verwendung
US4658830A (en) * 1984-08-08 1987-04-21 Survival Technology, Inc. Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms
AU584184B2 (en) * 1985-04-15 1989-05-18 Eli Lilly And Company An improved method for administering insulin
CA1274774A (en) * 1985-04-15 1990-10-02 Kenneth S. Su Method for administering insulin
GB2177914B (en) * 1985-06-04 1989-10-25 Chugai Pharmaceutical Co Ltd A pharmaceutical composition containing human erythropoietin and a surface active agent for nasal administration for the treatment of anemia
US4731360A (en) * 1985-08-16 1988-03-15 Merck & Co., Inc. Acylcarnitines as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal compartments
US4692441A (en) * 1985-08-16 1987-09-08 Merck & Co., Inc. Chorine esters as absorption-enhancing agents for drug delivery through mucous membranes of the nasal, buccal, sublingual and vaginal cavities
DK179286D0 (da) * 1986-04-18 1986-04-18 Nordisk Gentofte Insulinpraeparat
CA1291036C (en) * 1986-04-23 1991-10-22 Edwin I. Stoltz Nasal administration of drugs
US5179079A (en) * 1986-12-16 1993-01-12 Novo Nordisk A/S Nasal formulation and intranasal administration therewith
NZ222907A (en) * 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
CA1335076C (en) * 1987-04-01 1995-04-04 Hanna R. Kowarski Pharmaceutical composition and method for intranasal administration
US5112804A (en) * 1987-04-01 1992-05-12 Temple University Of The Commonwealth System Of Higher Education Pharmaceutical composition and method of intranasal administration
US6645504B1 (en) 1987-06-24 2003-11-11 Autoimmune Inc. Bystander suppression of type I diabetes by oral administration of glucagon
US4994439A (en) * 1989-01-19 1991-02-19 California Biotechnology Inc. Transmembrane formulations for drug administration
JPH0713372B2 (ja) * 1989-02-14 1995-02-15 鹿島建設株式会社 砂質土層における構造物基礎の構築方法
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
JPH04126437U (ja) * 1991-05-10 1992-11-18 八木アンテナ株式会社 光受信機
US5795870A (en) * 1991-12-13 1998-08-18 Trustees Of Princeton University Compositions and methods for cell transformation
US5693769A (en) * 1991-12-13 1997-12-02 Transcell Technologies, Inc. Glycosylated steroid derivatives for transport across biological membranes and process for making and using same
US5338837A (en) * 1991-12-13 1994-08-16 The Trustees Of Princeton University Glycosylated steroid derivatives for transport across biological membranes and process for making same
US6509006B1 (en) 1992-07-08 2003-01-21 Inhale Therapeutic Systems, Inc. Devices compositions and methods for the pulmonary delivery of aerosolized medicaments
US6582728B1 (en) 1992-07-08 2003-06-24 Inhale Therapeutic Systems, Inc. Spray drying of macromolecules to produce inhaleable dry powders
US5639866A (en) * 1993-02-23 1997-06-17 Princeton University Single-step formation of multiple glycosidic linkages
IL108748A0 (en) * 1993-02-23 1994-08-26 Univ Princeton Solution and solid-phase formation of glycosidic linkages
US5830853A (en) * 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US5747445A (en) * 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
JPH10501519A (ja) 1994-03-07 1998-02-10 インヘイル・セラピューティック・システムズ インシュリンを肺に送給できる方法および組成物
US6051256A (en) 1994-03-07 2000-04-18 Inhale Therapeutic Systems Dispersible macromolecule compositions and methods for their preparation and use
US6165976A (en) 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
JP3687993B2 (ja) * 1994-06-24 2005-08-24 シスメックス株式会社 インシュリン標準液
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
SK81197A3 (en) 1994-12-22 1997-11-05 Astra Ab Aerosol drug formulations, method for production thereof and its use
US5780014A (en) * 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
US7575761B2 (en) 2000-06-30 2009-08-18 Novartis Pharma Ag Spray drying process control of drying kinetics
DE10114178A1 (de) 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinkfreie und zinkarme Insulinzubereitungen mit verbesserter Stabilität
US6653492B2 (en) 2001-05-02 2003-11-25 Novo Nordick A/S Preparation of bile acids
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
DE10227232A1 (de) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Saure Insulinzubereitungen mit verbesserter Stabilität
DK3228320T3 (da) 2008-10-17 2020-03-09 Sanofi Aventis Deutschland Kombination af et insulin og en glp-1-agonist
PL3417871T3 (pl) 2009-11-13 2021-06-14 Sanofi-Aventis Deutschland Gmbh Kompozycja farmaceutyczna zawierająca agonistę GLP-1, insulinę i metioninę
CN102711804B (zh) 2009-11-13 2015-09-16 赛诺菲-安万特德国有限公司 包含glp-1激动剂和甲硫氨酸的药物组合物
RU2546520C2 (ru) 2010-08-30 2015-04-10 Санофи-Авентис Дойчланд Гмбх Применение ave0010 для производства лекарственного средства для лечения сахарного диабета 2 типа
JP5906194B2 (ja) * 2011-01-13 2016-04-20 株式会社カネカ 皮膚外用剤
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
BR112014004726A2 (pt) 2011-08-29 2017-04-04 Sanofi Aventis Deutschland combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
ES2949095T3 (es) 2014-12-12 2023-09-25 Sanofi Aventis Deutschland Formulación de relación fija de insulina glargina/lixisenatida
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL62232C (OSRAM) * 1900-01-01
US3096249A (en) * 1960-05-10 1963-07-02 Samuel J Prigal Emulsion composition

Also Published As

Publication number Publication date
JPS5225013A (en) 1977-02-24
JPS6030651B2 (ja) 1985-07-17
GB1527605A (en) 1978-10-04
BE841871A (fr) 1976-11-16
DE2620446A1 (de) 1977-03-03
FR2321275A1 (fr) 1977-03-18

Similar Documents

Publication Publication Date Title
CH604348A5 (OSRAM)
CH605376A5 (OSRAM)
BG22612A1 (OSRAM)
BG22639A1 (OSRAM)
BG22718A1 (OSRAM)
BG22739A1 (OSRAM)
BG22772A1 (OSRAM)
CH1169075A4 (OSRAM)
CH1355175A4 (OSRAM)
CH1422975A4 (OSRAM)
CH1545575A4 (OSRAM)
CH580351A5 (OSRAM)
CH582441A5 (OSRAM)
CH585959A5 (OSRAM)
CH588071A5 (OSRAM)
CH589012A5 (OSRAM)
CH589366A5 (OSRAM)
CH591652A5 (OSRAM)
CH592262A5 (OSRAM)
CH595173A5 (OSRAM)
CH595627A5 (OSRAM)
CH596833A5 (OSRAM)
CH596909A5 (OSRAM)
CH597790A5 (OSRAM)
CH598109A5 (OSRAM)

Legal Events

Date Code Title Description
ST Notification of lapse